Hirsutism Evaluation and Treatment Guidelines

What is the primary defining characteristic of hirsutism?

Which scoring method is considered the gold standard for evaluating hirsutism?

In the Ferriman–Gallwey score, what does a score of 0 indicate?

What percentage of the population is used as a threshold for diagnosing hirsutism?

For the treatment of hirsutism, which type of oral contraceptive (OC) is mentioned as equally effective?

How is excessive terminal hair classified when it appears in areas sensitive to androgens?

Which of the following is not a characteristic of hirsutism?

Which statement is true about antiandrogens compared to other oral contraceptives?

What is the effect of antiandrogenic progestins on hirsutism scores compared to other oral contraceptives?

How do androgenic progestins affect testosterone production?

What were the results of the trials pooling antiandrogens together in terms of effectiveness compared to placebo?

What is a possible clinical implication of the difference in hirsutism scores among various progestins?

What role does sex hormone-binding globulin (SHBG) play regarding androgens in serum?

What is one of the doses of spironolactone used to manage hirsutism?

Which progestin is noted to have a relatively androgenic effect among oral contraceptives?

What is a significant concern associated with flutamide use?

What is a proposed mechanism for how antiandrogenic progestins affect hirsutism?

Which dose of flutamide is most frequently used in randomized controlled trials?

In the treatment of hirsutism, what is a common recommendation regarding glucocorticoid therapy for women with classic congenital adrenal hyperplasia?

Which of the following statements about low-dose flutamide and hirsutism is accurate?

What role do glucocorticoids have in the management of women with nonclassic 21-hydroxylase deficiency?

What is the primary reason for using flutamide in combination therapies?

What percentage of women studied experienced elevated serum alanine aminotransferase and/or aspartate aminotransferase while taking low doses of flutamide?

What is a noted outcome of suppressing adrenal androgens in highly sensitive patients using glucocorticoids?

What is suggested against as initial therapy for most women with hirsutism?

What is the primary reason for not recommending antiandrogen monotherapy as initial therapy?

What should be considered when prescribing antiandrogen medication for women with hirsutism?

In the context of hirsutism, what condition may be evaluated through checking androgen levels?

What does the abbreviation 'NCCAH' stand for in the context of adrenal conditions?

What is the purpose of testing androgen levels in women presenting with hirsutism?

Which hormone is not typically related to hirsutism?

What does the acronym 'RCT' stand for in clinical studies related to hirsutism?

What is the expected prevalence of NCCAH among hyperandrogenic women?

What percentage of hirsute women are classified as having idiopathic hirsutism?

Which disorder must clinicians consider in the differential diagnosis when evaluating hirsutism?

What might exacerbate the features of PCOS in women?

What condition is characterized by androgen-secreting tumors, which are malignant in over half of the cases?

Which of the following hormonal conditions is least likely to be involved in the assessment of hirsutism?

What is the common hormonal change associated with hirsutism in women with no other clinical evidence of PCOS?

What percentage of eumenorrheic women with mild hirsutism may have idiopathic hirsutism?

What is the relationship between estrogen dose and VTE risk?

Which combined oral contraceptive does NOT refer to the content discussed?

What is a potential increased risk factor for VTE when using certain OCs?

Which type of progestins are linked to a higher VTE risk according to the text?

What does the evidence suggest about the risk posed by DSP in relation to VTE?

Which progestins are considered to have low androgenicity?

What conclusion did the Pharmacovigilance Risk Assessment Committee reach regarding CPA?

How does the absolute risk of VTE with combined OCs compare to that during pregnancy?